1. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real- world cost analysis and economic evaluation 
Prof Anna Vassall, PhD, Mariana Siapka, MSc, Nicola Foster, MSc, Lucy Cunnama, MSc, Lebogang Ramma, MSc, Prof Katherine Fielding, PhD, Kerrigan McCarthy, MSc, Prof Gavin Churchyard, PhD, Prof Alison Grant, PhD, Edina Sinanovic, PhD 
The Lancet Global Health 
Volume 5, Issue 7, Pages e710-e719 (July 2017)
DOI: /S X(17)30205-X
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1
Cost-effectiveness planes of Xpert versus sputum smear microscopy
Cost-effectivness planes showing the results of two different models of non-parametric two-stage bootstrapping using 10 000 replications to produce incremental costs per DALYs averted for Xpert versus sputum smear microscopy, with 3% (A) and 0% (B) discount rates. The x-axis represents the difference in DALYs averted, and the y-axis represents the difference in costs for the imputed data using 10 000 replications. Each point in the scatterplot represents one bootstrap iteration. Costs are in 2014 US$. DALY=disability-adjusted life-year.
The Lancet Global Health 2017 5, e710-e719DOI: ( /S X(17)30205-X)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2
Cost-effectiveness acceptability curves of Xpert versus sputum smear microscopy
The cost-effectiveness acceptability curves were generated by running 10 000 replications. The probability of Xpert being cost-effective was examined at different WTP thresholds, with 3% (A) and 0% (B) discount rates. Costs are in 2014 US$. WTP=willingness to pay. DALY=disability-adjusted life-year.
The Lancet Global Health 2017 5, e710-e719DOI: ( /S X(17)30205-X)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions